Tarsus Pharmaceuticals, Inc.
TARS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $118,697 | $102,660 | $78,335 | $66,408 |
| % Growth | 15.6% | 31.1% | 18% | – |
| Cost of Goods Sold | $24,593 | $6,237 | $5,211 | $4,926 |
| Gross Profit | $94,104 | $96,423 | $73,124 | $61,482 |
| % Margin | 79.3% | 93.9% | 93.3% | 92.6% |
| R&D Expenses | $16,284 | $15,594 | $14,409 | $16,873 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $108,633 | $103,013 | $84,995 | $69,030 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$16,284 | $0 | $0 | $0 |
| Operating Expenses | $108,633 | $118,607 | $99,404 | $85,903 |
| Operating Income | -$14,529 | -$22,184 | -$26,280 | -$24,421 |
| % Margin | -12.2% | -21.6% | -33.5% | -36.8% |
| Other Income/Exp. Net | $1,944 | $1,844 | $1,160 | $1,308 |
| Pre-Tax Income | -$12,585 | -$20,340 | -$25,120 | -$23,113 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$12,585 | -$20,340 | -$25,120 | -$23,113 |
| % Margin | -10.6% | -19.8% | -32.1% | -34.8% |
| EPS | -0.3 | -0.48 | -0.64 | -0.6 |
| % Growth | 37.5% | 25% | -6.7% | – |
| EPS Diluted | -0.3 | -0.48 | -0.64 | -0.6 |
| Weighted Avg Shares Out | 42,608 | 42,360 | 39,345 | 38,561 |
| Weighted Avg Shares Out Dil | 42,608 | 42,360 | 39,345 | 38,561 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,846 | $4,229 | $3,454 | $3,647 |
| Interest Expense | $0 | $2,094 | $2,074 | $2,174 |
| Depreciation & Amortization | $460 | $453 | $460 | $432 |
| EBITDA | -$12,125 | -$17,647 | -$22,447 | -$20,369 |
| % Margin | -10.2% | -17.2% | -28.7% | -30.7% |